Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - Deferred ChargesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Amortization - Deferred ChargesCost of RevenueEBIATGross ProfitMachine, Furnitures, Fixtures & OtherNon-Current ReceivablesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Fennec Pharmaceuticals (FENC) Gross Profit (2023 - 2025)

Fennec Pharmaceuticals filings provide 3 years of Gross Profit readings, the most recent being $7.7 million for Q4 2025.

  • On a quarterly basis, Gross Profit rose 92.69% to $7.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $32.0 million, a 13.59% decrease, with the full-year FY2025 number at $26.0 million, down 10.6% from a year prior.
  • Gross Profit hit $7.7 million in Q4 2025 for Fennec Pharmaceuticals, up from $7.3 million in the prior quarter.
  • In the past five years, Gross Profit ranged from a high of $24.8 million in Q1 2024 to a low of $1.6 million in Q1 2023.
  • Median Gross Profit over the past 3 years was $6.7 million (2023), compared with a mean of $7.4 million.
  • Biggest five-year swings in Gross Profit: skyrocketed 1469.34% in 2024 and later crashed 66.25% in 2025.
  • Fennec Pharmaceuticals' Gross Profit stood at $9.0 million in 2023, then tumbled by 56.01% to $4.0 million in 2024, then skyrocketed by 92.69% to $7.7 million in 2025.
  • The last three reported values for Gross Profit were $7.7 million (Q4 2025), $7.3 million (Q3 2025), and $8.7 million (Q2 2025) per Business Quant data.